Review
doi: 10.1177/030089161209800525.
Reversible posterior leukoencephalopathy syndrome following sunitinib therapy: a case report and review of the literature
Affiliations
- PMID: 23235770
- DOI: 10.1177/030089161209800525
Item in Clipboard
Review
Reversible posterior leukoencephalopathy syndrome following sunitinib therapy: a case report and review of the literature
Tumori.
2012 Sep-Oct.
Abstract
Sunitinib is one of the standard targeted therapies used in metastatic renal cell carcinoma. It is generally a reasonably tolerated oral systemic therapy but can be occasionally associated with life-threatening toxicities. We present a case of reversible posterior encephalopathy, which is a rare but recognised side effect of the treatment.
Similar articles
-
Severe neurological symptoms in a patient with advanced renal cell carcinoma treated with sunitinib.J Oncol Pharm Pract. 2013 Jun;19(2):186-9. doi: 10.1177/1078155212457967. Epub 2012 Oct 4. J Oncol Pharm Pract. 2013. PMID: 23037634
-
Reversible posterior leucoencephalopathy syndrome in an elderly male on sunitinib therapy.Br J Clin Pharmacol. 2011 May;71(5):777-9. doi: 10.1111/j.1365-2125.2010.03893.x. Br J Clin Pharmacol. 2011. PMID: 21480952 Free PMC article. Review.
-
Fatigue with sunitinib-induced hypothyroidism.Lancet Oncol. 2007 Feb;8(2):101. doi: 10.1016/s1470-2045(07)70016-5. Lancet Oncol. 2007. PMID: 17288042 No abstract available.
-
Response rates and adverse effects of continuous once-daily sunitinib in patients with advanced renal cell carcinoma: a single-center study in Turkey.Jpn J Clin Oncol. 2011 Dec;41(12):1380-7. doi: 10.1093/jjco/hyr151. Epub 2011 Oct 19. Jpn J Clin Oncol. 2011. PMID: 22013228
-
Sunitinib malate for the treatment of renal cell carcinoma.Expert Opin Pharmacother. 2012 Jun;13(9):1323-36. doi: 10.1517/14656566.2012.689130. Expert Opin Pharmacother. 2012. PMID: 22607009 Review.
Cited by
-
Posterior Reversible Encephalopathy Syndrome after Lenvatinib Therapy in a Patient with Olfactory Neuroblastoma.Brain Sci. 2022 Dec 23;13(1):33. doi: 10.3390/brainsci13010033. Brain Sci. 2022. PMID: 36672016 Free PMC article.
-
Axitinib-induced reversible posterior leukoencephalopathy syndrome in a patient with metastatic renal cell carcinoma.Int Cancer Conf J. 2017 Aug 2;6(4):197-199. doi: 10.1007/s13691-017-0306-x. eCollection 2017 Oct. Int Cancer Conf J. 2017. PMID: 31149502 Free PMC article.
-
Posterior reversible encephalopathy syndrome and takotsubo cardiomyopathy associated with lenvatinib therapy for thyroid cancer: a case report and review.Oncotarget. 2018 Jun 15;9(46):28281-28289. doi: 10.18632/oncotarget.25606. eCollection 2018 Jun 15. Oncotarget. 2018. PMID: 29963277 Free PMC article. Review.
-
Reversible Posterior Leukoencephalopathy Syndrome Developing After Restart of Sunitinib Therapy for Metastatic Renal Cell Carcinoma.Case Rep Med. 2016;2016:6852951. doi: 10.1155/2016/6852951. Epub 2016 Oct 4. Case Rep Med. 2016. PMID: 27795711 Free PMC article.
-
Anti-Angiogenic Tyrosine Kinase Inhibitors and Reversible Posterior Leukoencephalopathy Syndrome: Could Hypomagnesaemia Be the Trigger?Drug Saf. 2017 May;40(5):373-386. doi: 10.1007/s40264-017-0508-3. Drug Saf. 2017. PMID: 28181126 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
